BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 29424425)

  • 1. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
    Wu Y; Ju Q; Jia K; Yu J; Shi H; Wu H; Jiang M
    Int J Cancer; 2018 Jul; 143(1):45-51. PubMed ID: 29424425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Chen R; Hou X; Yang L; Zhao D
    Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Ren P; Liu D; Li W
    Cancer Med; 2019 Jul; 8(8):4023-4031. PubMed ID: 31165589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma.
    Zhang B; Zhou YL; Chen X; Wang Z; Wang Q; Ju F; Ren S; Xu R; Xue Q; Wu Q
    Int Immunopharmacol; 2019 Mar; 68():131-136. PubMed ID: 30622030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.
    Zhao B; Zhao H; Zhao J
    Int J Cancer; 2019 Jan; 144(1):169-177. PubMed ID: 30121946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting immune checkpoints in non small cell lung cancer.
    Bianco A; Malapelle U; Rocco D; Perrotta F; Mazzarella G
    Curr Opin Pharmacol; 2018 Jun; 40():46-50. PubMed ID: 29525401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.
    Roviello G; Andre F; Venturini S; Pistilli B; Curigliano G; Cristofanilli M; Rosellini P; Generali D
    Eur J Cancer; 2017 Nov; 86():257-265. PubMed ID: 29055841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.
    Corbaux P; Maillet D; Boespflug A; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Dalle S; Falandry C; Péron J
    Eur J Cancer; 2019 Nov; 121():192-201. PubMed ID: 31590080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
    Xu X; Huang Z; Zheng L; Fan Y
    Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
    Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
    Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
    Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.
    Afzal MZ; Mercado RR; Shirai K
    J Immunother Cancer; 2018 Jul; 6(1):64. PubMed ID: 29966520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
    Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
    Front Immunol; 2019; 10():108. PubMed ID: 30778352
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
    Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis.
    Ninomiya K; Oze I; Kato Y; Kubo T; Ichihara E; Rai K; Ohashi K; Kozuki T; Tabata M; Maeda Y; Kiura K; Hotta K
    Acta Oncol; 2020 Mar; 59(3):249-256. PubMed ID: 31782328
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
    Wu Y; Shi H; Jiang M; Qiu M; Jia K; Cao T; Shang Y; Shi L; Jiang K; Wu H
    Int J Cancer; 2017 Dec; 141(12):2562-2570. PubMed ID: 28833119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor doublets: Are they beneficial for older patients? A systematic review and meta-analysis.
    Dottorini L; Ghidini A; Deda R; Sarno I; Cavallone M; Luciani A; Petrelli F
    J Geriatr Oncol; 2024 May; 15(4):101741. PubMed ID: 38462434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.